These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 12172097)

  • 1. Generalized hair loss induced by indinavir plus ritonavir therapy.
    Ginarte M; Losada E; Prieto A; Lorenzo-Zúñiga V; Toribio J
    AIDS; 2002 Aug; 16(12):1695-6. PubMed ID: 12172097
    [No Abstract]   [Full Text] [Related]  

  • 2. Ritonavir and indinavir one year later.
    TreatmentUpdate; 2001; 12(12):6-7. PubMed ID: 11570094
    [No Abstract]   [Full Text] [Related]  

  • 3. Acute hepatitis in a patient treated with saquinavir and ritonavir: absence of cross-toxicity with indinavir.
    Vandercam B; Moreau M; Horsmans C; Gala JL
    Infection; 1998; 26(5):313. PubMed ID: 9795794
    [No Abstract]   [Full Text] [Related]  

  • 4. Once-a-day indinavir studied.
    AIDS Patient Care STDS; 2001 Jun; 15(6):340. PubMed ID: 11529195
    [No Abstract]   [Full Text] [Related]  

  • 5. Using ritonavir with indinavir in cases of virologic failure.
    TreatmentUpdate; 2001; 12(12):7. PubMed ID: 11570095
    [No Abstract]   [Full Text] [Related]  

  • 6. Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir.
    Aarnoutse RE; Wasmuth JC; Fätkenheuer G; Schneider K; Schmitz K; de Boo TM; Reiss P; Hekster YA; Burger DM; Rockstroh JK
    Antivir Ther; 2003 Aug; 8(4):309-14. PubMed ID: 14518700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy.
    Badía X; Podzamczer D; Moral I; Roset M; Arnaiz JA; Loncà M; Casiró A; Rosón B; Gatell JM;
    Antivir Ther; 2004 Dec; 9(6):979-85. PubMed ID: 15651756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience of indinavir/ritonavir 400/100 mg twice-daily highly active antiretroviral therapy-containing regimen in HIV-1-infected patients in Bamako, Mali: the NOGOMA Study.
    Canestri A; Cisse M; Marcelin AG; Peytavin G; Traore E; Assoumou L; Traore O; Koita V; Diallo F; Sangare AT; Sidibé MK; Calvez V; Sylla A; Katlama C; Tubiana R
    J Acquir Immune Defic Syndr; 2007 Aug; 45(4):477-9. PubMed ID: 17622837
    [No Abstract]   [Full Text] [Related]  

  • 9. A patient's guide to protease inhibitors.
    Elperin A; Sax P
    AIDS Clin Care; 1996 Oct; 8(10):83-4. PubMed ID: 11363988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hair loss in an HIV-1 infected woman receiving lopinavir plus ritonavir therapy as first line HAART.
    Bongiovanni M; Chiesa E; Monforte Ad; Bini T
    Dermatol Online J; 2003 Dec; 9(5):28. PubMed ID: 14996401
    [No Abstract]   [Full Text] [Related]  

  • 11. Once-daily indinavir plus ritonavir: preliminary results of the PIPO study.
    Burger DM; Hugen PW; van der Ende ME; van Wijngaarden P; Aarnoutse RE; Reiss P; Lange JM
    AIDS; 2000 Nov; 14(16):2621-3. PubMed ID: 11101081
    [No Abstract]   [Full Text] [Related]  

  • 12. Hair loss induced by lopinavir-ritonavir.
    Borrás-Blasco J; Belda A; Rosique-Robles D; Casterá E; Abad J; Amorós-Quiles I
    Pharmacotherapy; 2007 Aug; 27(8):1215-8. PubMed ID: 17655521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent activity but limited tolerance of ritonavir plus indinavir in salvage interventions.
    Barreiro P; Soriano V; Oller V; González-Lahoz J
    J Acquir Immune Defic Syndr; 2000 Aug; 24(5):488. PubMed ID: 11035621
    [No Abstract]   [Full Text] [Related]  

  • 14. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.
    Périard D; Telenti A; Sudre P; Cheseaux JJ; Halfon P; Reymond MJ; Marcovina SM; Glauser MP; Nicod P; Darioli R; Mooser V
    Circulation; 1999 Aug; 100(7):700-5. PubMed ID: 10449690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trials group: two studies are now open to patients who qualify.
    Craig K
    HIV Clin; 2000; 12(1):5. PubMed ID: 11810862
    [No Abstract]   [Full Text] [Related]  

  • 16. Indinavir use: associated reversible hair loss and mood disturbance.
    Harry TC; Matthews M; Salvary I
    Int J STD AIDS; 2000 Jul; 11(7):474-6. PubMed ID: 10919491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of indinavir and ritonavir administered at 667 and 100 milligrams, respectively, every 12 hours compared with indinavir administered at 800 milligrams every 8 hours in human immunodeficiency virus-infected patients.
    Rhame FS; Rawlins SL; Petruschke RA; Erb TA; Winchell GA; Wilson HM; Edelman JM; Abramson MA
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4200-8. PubMed ID: 15504842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ritonavir/indinavir combination study shows promising dosing results.
    AIDS Patient Care STDS; 1998 Feb; 12(2):146-7. PubMed ID: 11361915
    [No Abstract]   [Full Text] [Related]  

  • 19. Lopinavir/ritonavir- and indinavir-induced thrombocytopenia in a patient with HIV infection.
    Colebunders R; De Schacht C; Vanwolleghem T; Callens S
    Int J Infect Dis; 2004 Sep; 8(5):315-6. PubMed ID: 15325601
    [No Abstract]   [Full Text] [Related]  

  • 20. Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily.
    Konopnicki D; De Wit S; Poll B; Crommentuyn K; Huitema A; Clumeck N
    HIV Med; 2005 Jan; 6(1):1-6. PubMed ID: 15670245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.